Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Boucai

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of Surgical Oncology|September 11, 2020
Predicting malignancy in patients with adrenal tumors using <sup>18</sup> F-FDG-PET/CT SUVmaxElvira L Vos, Ravinder K Grewal, Ashley E Russo, et al.
The Journal of Clinical Investigation|November 8, 2011
Activation of K(ATP) channels suppresses glucose production in humansPreeti Kishore, Laura Boucai, Kehao Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine TherapyLaura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
The Journal of Clinical Endocrinology and Metabolism|June 26, 2019
Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node MetastasesDilmi Perera, Ronald Ghossein, Niedzica Camacho, et al.
The Lancet. Diabetes & Endocrinology|May 3, 2025
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statementSophie Leboulleux, Laura Boucai, Naifa Busaidy, et al.
The Journal of Clinical Investigation|February 16, 2016
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersIñigo Landa, Tihana Ibrahimpasic, Laura Boucai, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Thyroid : Official Journal of the American Thyroid Association|September 30, 2022
Active Surveillance of Papillary Thyroid Cancer: Frequency and Time Course of the Six Most Common Tumor Volume Kinetic PatternsRobert Michael Tuttle, James Fagin, Gerald Minkowitz, et al.
JAMA Otolaryngology-- Head & Neck Surgery|September 1, 2017
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active SurveillanceR Michael Tuttle, James A Fagin, Gerald Minkowitz, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of Surgical Oncology|September 11, 2020
Predicting malignancy in patients with adrenal tumors using <sup>18</sup> F-FDG-PET/CT SUVmaxElvira L Vos, Ravinder K Grewal, Ashley E Russo, et al.
The Journal of Clinical Investigation|November 8, 2011
Activation of K(ATP) channels suppresses glucose production in humansPreeti Kishore, Laura Boucai, Kehao Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine TherapyLaura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
The Journal of Clinical Endocrinology and Metabolism|June 26, 2019
Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node MetastasesDilmi Perera, Ronald Ghossein, Niedzica Camacho, et al.
The Lancet. Diabetes & Endocrinology|May 3, 2025
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statementSophie Leboulleux, Laura Boucai, Naifa Busaidy, et al.
The Journal of Clinical Investigation|February 16, 2016
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersIñigo Landa, Tihana Ibrahimpasic, Laura Boucai, et al.
Biorxiv : the Preprint Server for Biology|March 17, 2025
Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitorsVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
The Journal of Clinical Investigation|August 19, 2025
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancersVera Tiedje, Jillian Greenberg, Tianyue Qin, et al.
Thyroid : Official Journal of the American Thyroid Association|September 30, 2022
Active Surveillance of Papillary Thyroid Cancer: Frequency and Time Course of the Six Most Common Tumor Volume Kinetic PatternsRobert Michael Tuttle, James Fagin, Gerald Minkowitz, et al.
JAMA Otolaryngology-- Head & Neck Surgery|September 1, 2017
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active SurveillanceR Michael Tuttle, James A Fagin, Gerald Minkowitz, et al.
Pageof 6